Phase 3 Readout

Phase 3 Topline: An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Eff

Indication
PNH

Other upcoming events for APLS

Phase 3 ReadoutPhase 3 Topline: An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Effic
Phase 3 ReadoutPhase 3 Topline: A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Con
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficac
Patent ExpiryPatent/Exclusivity Expiry: SYFOVRE
Patent ExpiryPatent/Exclusivity Expiry: EMPAVELI

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Eff — APLS Phase 3 Readout | BioSniper